About RadioClash
RadioClash is developing a cancer treatment it calls Combination Electroporation Therapy. The approach shocks a tumor, then delivers drugs straight into it to kill more cancer cells and trigger an immune response throughout the body. Its Electro-Embolizer Device is a minimally invasive surgical tool meant to carry out this therapy, starting with cancers of the liver, pancreas, and bones.
The company is based in Houston, Texas. Physician Yang Qiao, who trains in interventional radiology at the University of Texas Health Science, is the chief executive officer. Duane Bester, who graduated from Texas A&M in electrical engineering in 2011, is the chief technology officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Nov 3, 2026 | $99,999of $3.5M target | 1 | $99,999 | EquityRule 506(b) | Form D ↗ |
| Oct 28, 2024 | Nov 8, 2024amended Dec 1, 2025 | $1,377,757of $2.7M target | 28 | $49,206 | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $1,477,756 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed RadioClash
RadioClash is a Houston medical device company building a cancer treatment it calls Combination Electroporation Therapy. Its Electro-Embolizer Device is meant to deliver this therapy straight into tumors in the liver, pancreas, and bones. Physician Yang Qiao is the company's chief executive officer, and Duane Bester, an electrical engineer trained at Texas A&M, is its chief technology officer.
The problem it targets
Yang Qiao, RadioClash's founder, argues that open surgical treatments for cancer cause more pain and complications than his approach would. He says years of performing minimally invasive procedures and treating patients convinced him that combination electroporation therapy could give people with cancer that has spread a new way to fight it.
Progress so far
In 2021, RadioClash won the Columbia-CareOne Healthcare Innovation Challenge, part of the Columbia Venture Competition. Judges put virtual investment dollars behind six competing health care startups, and RadioClash drew the most support, earning a $25,000 cash prize.
We wrote this summary from public statements by RadioClash and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on RadioClash's Form D filed Nov 3, 2026.
Earlier filings also listed Samantha Jayawickrama (executive officer, last listed Dec 2025).